Professional Documents
Culture Documents
Sinovac Vaccine Explainer
Sinovac Vaccine Explainer
11 JUNE 20211
Preliminary findings from a post-introduction cohort study in Chile that involved about 2.5 million individuals
that had received two doses and 2.1 million individuals that received one dose (≥16 years), suggest vaccine
effectiveness starting 14 days after the second dose to be 67% against symptomatic SARS-CoV-2 infections,
85% against hospitalization, and 80% against death. Protection 14 days after the first dose was limited, up to
administration of the second dose.
The data reviewed at this time support the conclusion that the known and potential benefits of CoronaVac®
vaccine outweigh the risks that are known or considered possible.
Product characteristics
Presentation Fully liquid, inactivated, adjuvanted, preservative-free suspension for injection in
vials and non-AD pre-filled syringes
Number of doses Single-dose (one dose 0.5 mL)
Vaccine syringe type Two available presentations:
and needle size 1. Non-auto-disable (non-AD) syringe: 0.5 mL
2. Vials, for which the following is needed:
• Auto-disable (AD) syringes: 0.5 mL
• Needles for intramuscular injection 23G × 1” (0.60 × 25 mm)
1
Contents will be updated as new information becomes available.
1/6
COVID-19 Vaccine Explainer
11 JUNE 2021
If the second dose is inadvertently administered earlier than 2 weeks after the first,
the dose does not need to be repeated.
If the second dose is inadvertently delayed beyond 4 weeks, it should be given at
the earliest possible opportunity.
2/6
COVID-19 Vaccine Explainer
11 JUNE 2021
3/6
COVID-19 Vaccine Explainer
11 JUNE 2021
4/6
COVID-19 Vaccine Explainer
11 JUNE 2021
Safety information*
Possible events Observed events frequent, mostly mild to moderate and short lived
(by frequency)
Very common (≥1/10):
Headache, pain at the injection site, fatigue
Common (≥1/100 to ˂1/10):
Injection site: swelling, itching, redness, induration; chills, myalgia, arthralgia,
nasal congestion, cough, runny nose, sore throat, pruritus, loss of appetite,
nausea, diarrhoea, abdominal pain
Uncommon (≥1/1 000 to ˂1/100):
Injection site: warmth, swelling; fever ≥37.3 °C, tremor, dizziness, drowsiness,
flushing, vomiting, mucocutaneous rash, hypersensitivity
Rare (≥1/10 000 to ˂ 1/1 000):
Ocular congestion, eyelid swelling, hot flashes, nose bleeds, diminished sense of
smell, abdominal distension, constipation, muscle spasms
Not known (cannot be estimated from available data):
Anaphylaxis
Important reminders
Vaccination session and vaccine administration:
Before, during, and after vaccination, all people should continue to follow current guidance for protection
from COVID-19 in their area (e.g. wearing a mask, keeping physical distance, hand hygiene).
Vaccination should be offered regardless of a person’s history of symptomatic or asymptomatic SARS-
CoV-2 infection. Viral or serological testing is not recommended for the purpose of decision-making about
vaccination. Based on available data, symptomatic reinfection in uncommon within 6 months after an initial
natural infection, and in the context of limited vaccine supply, persons with PCR-confirmed SARS-CoV-2
infection in the preceding 6 months may choose to delay vaccination until near the end of this period.
However, emerging data indicate that symptomatic reinfection may occur in settings where variants with
evidence of immune escape are circulating, and in these settings, earlier vaccination after infection may
be advisable. The length of this time period may be revised when more data on duration of immunity after
natural infection become available.
The presence of a minor infection such as a cold or low-grade fever should not delay vaccination.
A person with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from
acute illness and the criteria for discontinuation of isolation have been met. The optimal minimum interval
between a natural infection and vaccination is not yet known.
Before vaccination, advise vaccine recipient about possible post-vaccination symptoms and observe post-
vaccination for at least 15 minutes.
5/6
COVID-19 Vaccine Explainer
11 JUNE 2021
SARS-CoV-2 variants
As SARS-CoV-2 viruses undergo evolution, new variants may be associated with higher transmissibility,
disease severity, risk of reinfection, or a change in antigenic composition. At the time of the clinical trial in
Brazil, the variant of concern P.1 was just starting to emerge and other variants of concern (e.g. B.1.1.7 and
B1.351) were not circulating.
Preliminary findings from vaccine effectiveness study in Manaus, Brazil estimated effectiveness of
CoronaVac® to be 49.6% against symptomatic infection following at least one dose and in the context of
broad circulation of the P.1 variant (P.1 accounted for 75% of genotyped SARS-CoV-2 samples at the peak
of its epidemic in January 2021). Vaccine effectiveness assessed in a cohort of health workers in Sao Paulo,
Brazil was 50.7% two weeks after the second dose, also in the context of circulating variants of concern,
mainly P.1. High vaccine effectiveness against hospitalizations and deaths demonstrated in post-introduction
study in Chile was in the context of circulating B.1.1.7 and P.1.
WHO currently recommends the use of CoronaVac® even if the variants are present in the country.
Countries should conduct a benefit-risk assessment according to the local epidemiological situation
including the extent of circulating virus variants. Countries using the vaccine in the presence of variants are
encouraged to monitor vaccine effectiveness and study eventual breakthrough infections due to variants.
SARS-CoV-2 tests
CoronaVac® contains inactivated SARS-CoV-2 virus which elicits immunological response to the spike and
nucleocapsid protein. As currently available antibody tests for SARS-CoV-2 assess levels of IgM and/or
IgG to the spike or the nucleocapsid protein, a positive test could indicate either prior infection or prior
vaccination. Antibody testing is not currently recommended to assess immunity to COVID-19 following
CoronaVac® vaccination.
6/6